Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia.

NCT06456528 is registered in ClinicalTrials.gov with Qilu Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06456528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06456528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia.
Lead sponsor
Qilu Pharmaceutical Co., Ltd.
Phase
Phase 2/3
Overall status
Recruiting
Start date
October 22, 2024
Completion date
July 30, 2027
Enrollment
235 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer treatment-induced thrombocytopenia